JP2022537269A5 - - Google Patents
Info
- Publication number
- JP2022537269A5 JP2022537269A5 JP2021573213A JP2021573213A JP2022537269A5 JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5 JP 2021573213 A JP2021573213 A JP 2021573213A JP 2021573213 A JP2021573213 A JP 2021573213A JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- muc16
- cancer
- agonist
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144172A JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864960P | 2019-06-21 | 2019-06-21 | |
| US62/864,960 | 2019-06-21 | ||
| PCT/US2020/038669 WO2020257604A1 (en) | 2019-06-21 | 2020-06-19 | Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144172A Division JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537269A JP2022537269A (ja) | 2022-08-25 |
| JP2022537269A5 true JP2022537269A5 (enExample) | 2023-06-20 |
| JP7743314B2 JP7743314B2 (ja) | 2025-09-24 |
Family
ID=71842848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573213A Active JP7743314B2 (ja) | 2019-06-21 | 2020-06-19 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| JP2024144172A Pending JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144172A Pending JP2024164188A (ja) | 2019-06-21 | 2024-08-26 | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12091460B2 (enExample) |
| EP (1) | EP3986934A1 (enExample) |
| JP (2) | JP7743314B2 (enExample) |
| KR (1) | KR20220024035A (enExample) |
| CN (2) | CN118453851A (enExample) |
| AU (1) | AU2020294790A1 (enExample) |
| CA (1) | CA3140083A1 (enExample) |
| IL (2) | IL288916B2 (enExample) |
| MA (1) | MA56537A (enExample) |
| MX (1) | MX2021015270A (enExample) |
| WO (1) | WO2020257604A1 (enExample) |
| ZA (1) | ZA202108895B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| WO2022197907A2 (en) * | 2021-03-18 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors |
| IL315405A (en) * | 2022-03-17 | 2024-11-01 | Regeneron Pharma | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies |
| WO2024051752A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
| WO2025082777A1 (en) * | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| TW202542187A (zh) * | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP3131585B1 (en) | 2014-03-19 | 2020-07-15 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| RU2743781C2 (ru) * | 2014-06-10 | 2021-02-25 | 3Б Фармасьютикалз Гмбх | Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение |
| US9980930B2 (en) * | 2014-10-16 | 2018-05-29 | The University Of Melbourne | Imaging composition and uses thereof |
| SG11201707538XA (en) | 2015-03-17 | 2017-10-30 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| EP4649966A3 (en) * | 2016-12-01 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| AU2017380981B2 (en) * | 2016-12-19 | 2025-01-30 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1BB (CD137) agonists |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
-
2020
- 2020-06-19 EP EP20747267.1A patent/EP3986934A1/en active Pending
- 2020-06-19 MA MA056537A patent/MA56537A/fr unknown
- 2020-06-19 IL IL288916A patent/IL288916B2/en unknown
- 2020-06-19 MX MX2021015270A patent/MX2021015270A/es unknown
- 2020-06-19 AU AU2020294790A patent/AU2020294790A1/en active Pending
- 2020-06-19 JP JP2021573213A patent/JP7743314B2/ja active Active
- 2020-06-19 KR KR1020217040895A patent/KR20220024035A/ko active Pending
- 2020-06-19 CN CN202410406230.1A patent/CN118453851A/zh active Pending
- 2020-06-19 US US16/906,634 patent/US12091460B2/en active Active
- 2020-06-19 WO PCT/US2020/038669 patent/WO2020257604A1/en not_active Ceased
- 2020-06-19 CA CA3140083A patent/CA3140083A1/en active Pending
- 2020-06-19 CN CN202080045426.2A patent/CN113993547B/zh active Active
-
2021
- 2021-11-10 ZA ZA2021/08895A patent/ZA202108895B/en unknown
-
2024
- 2024-08-19 US US18/809,063 patent/US20250042999A1/en active Pending
- 2024-08-26 JP JP2024144172A patent/JP2024164188A/ja active Pending
-
2025
- 2025-10-09 IL IL323844A patent/IL323844A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537269A5 (enExample) | ||
| JP2021166522A (ja) | キメラ抗原受容体組成物 | |
| JP2022017295A (ja) | Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法 | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP2022537019A5 (enExample) | ||
| JP2021519076A5 (enExample) | ||
| JP2016509582A5 (enExample) | ||
| TW200813090A (en) | Combinatorial therapy | |
| JP2021523100A5 (enExample) | ||
| JP2022527081A (ja) | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） | |
| JP7374765B2 (ja) | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 | |
| RU2682161C2 (ru) | Противоопухолевое средство и усилитель противоопухолевого эффекта | |
| AU2020228296B2 (en) | Administration of PD-1 inhibitors for treating skin cancer | |
| JP2024546605A5 (enExample) | ||
| JP2022543765A5 (enExample) | ||
| JPWO2016104657A1 (ja) | 癌治療剤 | |
| JP2025515092A5 (enExample) | ||
| WO2022233262A1 (zh) | 抗体药物偶联物治疗癌症的方法及用途 | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2025501978A5 (enExample) | ||
| WO2019214492A1 (zh) | 抗her2抗体-药物偶联物在治疗癌症中的用途 | |
| JP2003520250A (ja) | 一部の癌の治療における抗フェリチンモノクローナル抗体の使用 | |
| WO2021057764A1 (zh) | Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途 | |
| US20240100053A1 (en) | Pharmaceutical composition | |
| RU2021132494A (ru) | Применение биспецифических антигенсвязывающих молекул, которые связывают muc16 и cd3, в комбинации с костимуляцией 4-1bb |